

**Acknowledgement of your Submission to RSC Advances - RA-ART-09-2022-005673**

1 message

RSC Advances &lt;onbehalf@manuscriptcentral.com&gt;

Thu, Sep 8, 2022 at 7:29 PM

Reply-To: advances@rsc.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com, putriindrawasih@gmail.com, M11006808@mail.ntust.edu.tw, musbahu.adam.ahmad-2020@fst.unair.ac.id, satya.sakti@fst.unair.ac.id, jychang@mail.ntust.edu.tw

08-Sep-2022

Dear Mr Fahmi:

TITLE: Naproxen Release Study upon Carbon dots coated Magnetite Nanohybrid as Versatile Theranostic of HeLa Cancer Cells

Thank you for your submission to RSC Advances, published by the Royal Society of Chemistry. This is an automatic acknowledgement that you have uploaded your files to our online submission system. Your manuscript ID is: RA-ART-09-2022-005673

Your manuscript will be passed to an editor for initial assessment as soon as possible. If there are any problems with your submission we will contact you.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>

Please indicate the above manuscript ID when you contact us about this submission.

Do you have an ORCID iD? ORCID (Open Researcher and Contributor iD) is a unique researcher identifier that allows you to link your research output and other professional activities in a single record. We therefore encourage each researcher to sign up for their own ORCID account. Please edit your user account to link your ORCID iD or create a new one, ensuring that you have not linked your account to another researcher's ORCID iD. Please note that we are unable to do this on your behalf. If your article is accepted, you may choose to have your ORCID record updated automatically with details of the publication.

We already have the following information for authors of this manuscript: Fahmi, Mochamad Zakki - <https://orcid.org/0000-0001-5430-9992>, Machmudah, Nurlailatul - No ORCID iD Available, Indrawasih, Putri - No ORCID iD Available, Wibrianto, Aswandi - <https://orcid.org/0000-0002-7746-7405>, Ahmad, Musbahu - <https://orcid.org/0000-0003-2875-9572>, Sakti, Satya Candara - No ORCID iD Available, Chang, Jia-Yaw - No ORCID iD Available

If this is not how you want your name to appear on an Accepted Manuscript, please amend your ScholarOne account.

The Royal Society of Chemistry is a member of CrossCheck. Your submission may be compared against the CrossCheck database using the iThenticate plagiarism detection software. For further information, please see here: <https://www.rsc.org/journals-books-databases/journal-authors-reviewers/processes-policies/#crosscheck>

This journal has a policy of sharing reviewer reports. Please note that the Editor's decision and copies of the reports will be shared with all reviewers who provide a recommendation on your manuscript.

Please contact us if we can be of any assistance.

Yours sincerely,  
RSC Advances Editorial Office  
[advances@rsc.org](mailto:advances@rsc.org)

If you need to contact the journal, please use the email address [advances@rsc.org](mailto:advances@rsc.org)

\*\*\*\*\*

**DISCLAIMER:**

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: [www.rsc.org](http://www.rsc.org)

**Decision on submission to RSC Advances - RA-ART-09-2022-005673**

1 message

RSC Advances <onbehalf@manuscriptcentral.com>  
Reply-To: advances@rsc.org  
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Sat, Oct 15, 2022 at 12:14 PM

15-Oct-2022

Dear Mr Fahmi:

Manuscript ID: RA-ART-09-2022-005673

TITLE: Naproxen Release Study upon Carbon dots coated Magnetite Nanohybrid as Versatile Theranostic of HeLa Cancer Cells

Thank you for your submission to RSC Advances, published by the Royal Society of Chemistry. I sent your manuscript to reviewers and I have now received their reports which are copied below.

I have carefully evaluated your manuscript and the reviewers' reports, and the reports indicate that major revisions are necessary.

Please submit a revised manuscript which addresses all of the reviewers' comments. Further peer review of your revised manuscript may be needed. When you submit your revised manuscript please include a point by point response to the reviewers' comments and highlight the changes you have made. Full details of the files you need to submit are listed at the end of this email.

Please submit your revised manuscript as soon as possible using this link:

\*\*\* PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. \*\*\*

[https://mc.manuscriptcentral.com/rscadv?URL\\_MASK=c9973cd28d06411b8c125c610806de1c](https://mc.manuscriptcentral.com/rscadv?URL_MASK=c9973cd28d06411b8c125c610806de1c)

(This link goes straight to your account, without the need to log on to the system. For your account security you should not share this link with others.)

Alternatively, you can log in to your account (<https://mc.manuscriptcentral.com/rscadv>) where you will need your case-sensitive user ID and password details.

You should submit your revised manuscript as soon as possible; please note you will receive a series of automatic reminders. If your revisions will take a significant length of time, please contact me.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>

RSC Advances strongly encourages authors of research articles to include an 'Author contributions' section in their manuscript, for publication in the final article. This should appear immediately above the 'Conflict of interest' and 'Acknowledgement' sections. I strongly recommend you use CRediT (the Contributor Roles Taxonomy, <https://credit.niso.org/>) for standardised contribution descriptions. All authors should have agreed to their individual contributions ahead of submission and these should accurately reflect contributions to the work. Please refer to our general author guidelines <https://www.rsc.org/journals-books-databases/author-and-reviewer-hub/authors-information/responsibilities/> for more information.

The Royal Society of Chemistry requires the submitting author to provide their ORCID iD when they submit a revised manuscript. This is quick and easy to do as part of the revised manuscript submission process. We will publish this information with the article, and you may choose to have your ORCID record updated automatically with details of the publication.

Please also encourage your co-authors to sign up for their own ORCID account and associate it with their account on our manuscript submission system. Please note that we are unable to do this on behalf of your co-authors. For further information see: <https://www.rsc.org/journals-books-databases/journal-authors-reviewers/processes-policies/#attribution-id>.

I look forward to receiving your revised manuscript.

Yours sincerely,  
Prof Andrea Pucci  
Associate Editor, RSC Advances

\*\*\*\*\*

REVIEWER REPORT(S):

Referee: 1

Recommendation: Major revisions

Comments:

This work reports the naproxen release study upon carbon dots coated magnetite nanohybrid as versatile theranostic of Hela cancer cells. The study is significant. However, some results of this assay are not and should be improved. A revision is required before the manuscript can be accepted.

1. What is the mechanism of forming Fe<sub>3</sub>O<sub>4</sub>@CDs? The authors should describe the mechanism in detail in the manuscript.
2. The authors can provide the cellular image of Fe<sub>3</sub>O<sub>4</sub>@CDs in Hela cancer cells.
3. At present, Fe<sub>3</sub>O<sub>4</sub>@CDs have been applied in many fields, and the author should introduce more about the application of carbon dots in the Introduction. Some articles can be cited in the manuscript, such as: Journal of Materials Chemistry B, 2022, 10, 5251-5262. Frontiers in bioengineering and biotechnology, 2020, 8: 614906. ACS Sustainable Chem. Eng. 2022, 10, 12, 3935-3950. Frontiers in chemistry, 2021, 9, 769648. Applied Organometallic Chemistry, 2021, 35(11): e6387. Food Chemistry, 2022, 373: 131415. Dalton Trans., 2016, 45, 5484-5491. RSC advances, 2016, 6(85): 82294-82297. New J. Chem., 2020, 44, 6635-6642. RSC Adv., 2018, 8, 8528-8536. RSC Adv., 2017, 7, 41304-41310, and so on.

Additional Questions:

Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: Yes

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds>: Yes

Is the experimental section sufficiently detailed to allow others to reproduce the work?: Yes

Are the reported claims adequately discussed in the context of the literature?: No

Are the number of tables and figures in the manuscript appropriate and clear?: Yes

Referee: 2

Recommendation: Major revisions

Comments:

1. TEM, UV and PL spectra of Fe<sub>3</sub>O<sub>4</sub>@CA should be studied in this work.
2. Fe<sub>3</sub>O<sub>4</sub>@CDs or CDs@Fe<sub>3</sub>O<sub>4</sub>? The author should be unified and proved in the manuscript.
3. HRTEM and Mapping of Materials should be studied in this work.
4. Fe<sub>3</sub>O<sub>4</sub>@CDs have been reported in many articles. Please refer to the latest references.
5. Cellular image of Fe<sub>3</sub>O<sub>4</sub>@CDs in cells should be provide in the manuscript.
6. Synthesis mechanism of materials must be provide in the manuscript.

Additional Questions:

Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: Yes

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds>: No

Is the experimental section sufficiently detailed to allow others to reproduce the work?: Yes

Are the reported claims adequately discussed in the context of the literature?: No

Are the number of tables and figures in the manuscript appropriate and clear?: No

\*\*\*\*\*

FILES TO PROVIDE WITH YOUR REVISED MANUSCRIPT:

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission. Please carefully check the spelling and format of all author names, affiliations and funding

information. If your paper is accepted for publication, it is important this information is accurate to ensure your article is correctly indexed, which may affect citations and future funding evaluation. Please note that if you have selected Accepted Manuscript publication, the author list will appear as provided in the ScholarOne submission details until your Advance Article is published and this information is updated from your article.

- A point-by-point response to the comments made by the reviewer(s)
- Your revised manuscript with any changes clearly marked (.doc(x) or .pdf file)
- Your revised manuscript as a .doc(x) file including figures, without highlighting, track changes, etc. (If providing in TeX format instead, please also provide a final PDF version including figures). Please note that we cannot proceed with publication using a .pdf file only.

High quality images

EITHER  
embedded in a doc(x) file  
OR  
as separate numbered Figures, Schemes or Charts in .tif, .eps or .pdf format, with a resolution of 600 dpi or greater.

AND

- A table of contents entry: graphic maximum size 8 cm x 4 cm and 1-2 sentence(s) of editable text, with a maximum of 250 characters (including spaces), highlighting the key findings of the work. It is recommended authors make use of the full space available for the graphic. See our Author Guidelines for more details: <https://www.rsc.org/journals-books-databases/author-and-reviewer-hub/>
- Your revised Electronic Supplementary Information (if any)
- Your revised CheckCIF reports (if any). Please ensure that any revised cif files have been deposited with the Cambridge Crystallographic Data Centre (CCDC) via <https://deposit.ccdc.cam.ac.uk/> before you submit your revised manuscript.

For Review-type articles only:

- A photograph and biography of yourself and your co-authors. Separate photographs of each author may be supplied or if you prefer, a group photograph, saved as a .tif, .pdf or .jpeg file. The resolution of the photographs should be 600 dpi or higher. The dimensions of the photograph in the printed journal will be 4 cm wide x 5 cm high (individual photograph) or 8.3 cm wide x 5 cm high (group photograph). Individual photographs should be accompanied by a maximum of 100 words; a group photograph by a maximum of 200 words. There can be a maximum of 6 individual biographies per article.
- Copies of permissions required from other publishers to reproduce figures. Please ensure that necessary permissions are acknowledged in the figure captions in accordance with the publishers' instruction. Information on how to obtain permissions and rights that we require are given on our website at <https://www.rsc.org/journals-books-databases/journal-authors-reviewers/licences-copyright-permissions/>

\*\*\*\*\*

If you need to contact the journal, please use the email address [advances@rsc.org](mailto:advances@rsc.org)

\*\*\*\*\*

DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: [www.rsc.org](http://www.rsc.org)

## Acknowledgement of your revised manuscript submission to RSC Advances - RA-ART-09-2022-005673.R1

1 message

RSC Advances <onbehalf@manuscriptcentral.com>

Mon, Oct 24, 2022 at 5:09 PM

Reply-To: advances@rsc.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com, nurlailiatul.m-2014@fst.unair.ac.id, putriindrawasih@gmail.com, aswandi.wibrianto-2016@fst.unair.ac.id, M11006808@mail.ntust.edu.tw, musbahu.adam.ahmad-2020@fst.unair.ac.id, satya.sakti@fst.unair.ac.id, jychang@mail.ntust.edu.tw

24-Oct-2022

Dear Mr Fahmi:

TITLE: Naproxen Release Study upon Carbon dots coated Magnetite Nanohybrid as Versatile Theranostic of HeLa Cancer Cells  
AUTHORS: Fahmi, Mochamad Zakki; Machmudah, Nurlailiatul; Indrawasih, Putri; Wibrianto, Aswandi; Ahmad, Musbahu; Sakti, Satya Candara; Chang, Jia-Yaw

Thank you for your revised submission to RSC Advances, published by the Royal Society of Chemistry. This is an automatic acknowledgement that you have uploaded your files to our online submission system. Your manuscript ID is: RA-ART-09-2022-005673.R1

Your manuscript will be passed to an editor for initial assessment as soon as possible. If there are any problems with your submission we will contact you.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>

Please indicate the above manuscript ID when you contact us about this submission.

If there have been any changes to the list of authors during this revision, please inform the Editorial Office of the reason for the change. All authors must confirm they are happy with the authorship change by emailing [advances@rsc.org](mailto:advances@rsc.org).

Do you have an ORCID iD? ORCID (Open Researcher and Contributor iD) is a unique researcher identifier that allows you to link your research output and other professional activities in a single record. We therefore encourage each researcher to sign up for their own ORCID account. Please edit your user account to link your ORCID iD or create a new one, ensuring that you have not linked your account to another researcher's ORCID iD. Please note that we are unable to do this on your behalf. If your article is accepted, you may choose to have your ORCID record updated automatically with details of the publication.

We already have the following information for authors of this manuscript: Fahmi, Mochamad Zakki - <https://orcid.org/0000-0001-5430-9992>, Machmudah, Nurlailiatul - No ORCID iD Available, Indrawasih, Putri - No ORCID iD Available, Wibrianto, Aswandi - <https://orcid.org/0000-0002-7746-7405>, Ahmad, Musbahu - <https://orcid.org/0000-0003-2875-9572>, Sakti, Satya Candara - No ORCID iD Available, Chang, Jia-Yaw - No ORCID iD Available

If this is not how you want your name to appear on an Accepted Manuscript, please amend your ScholarOne account.

This journal has a policy of sharing reviewer reports. Please note that the Editor's decision and copies of the reports will be shared with all reviewers who provide a recommendation on your manuscript.

Please contact us if we can be of any assistance.

Yours sincerely,

RSC Advances Editorial Office

[advances@rsc.org](mailto:advances@rsc.org)

If you need to contact the journal, please use the email address [advances@rsc.org](mailto:advances@rsc.org)

\*\*\*\*\*

### DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society

of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: [www.rsc.org](http://www.rsc.org)



**Decision on submission to RSC Advances - RA-ART-09-2022-005673.R1**

1 message

RSC Advances <onbehalf@manuscriptcentral.com>  
Reply-To: advances@rsc.org  
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Thu, Oct 27, 2022 at 9:17 PM

27-Oct-2022

Dear Mr Fahmi:

Manuscript ID: RA-ART-09-2022-005673.R1

TITLE: Naproxen Release Study upon Carbon dots coated Magnetite Nanohybrid as Versatile Theranostic of HeLa Cancer Cells

Thank you for submitting your revised manuscript to RSC Advances. I am pleased to accept your manuscript for publication in its current form. I have copied any final comments from the reviewer(s) below.

You will shortly receive a separate email from us requesting you to submit a licence to publish for your article, so that we can proceed with the preparation and publication of your manuscript. We will email you information on how to access your RSC Advances article proofs when they are ready.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>.

How can we improve our open access publishing service for you?

Share your OA feedback in a short telephone interview in English or Mandarin to help us improve our open access publishing processes and receive a £25 Amazon voucher (or local equivalent) for your time. Find out more here: <https://www.smartsurvey.co.uk/s/OpenAccess>.

We are offering all corresponding authors who are not already members of the Royal Society of Chemistry one year's Affiliate membership as part of their APC. If you would like to find out more please email [membership@rsc.org](mailto:membership@rsc.org), including the promo code OA100 in your message. Learn all about our member benefits at <https://www.rsc.org/membership-and-community/join/#benefit>.

Promote your research, accelerate its impact – find out more about our article promotion services here: <https://rsc.li/promoteyourresearch>.

If you would like us to promote your article on our Twitter account @RSCAdvances please fill out this form: <https://form.jotform.com/212705294847058>. Alternatively, if you would like your article to be considered for further promotion via our WeChat channels then please do let us know.

By publishing your article in RSC Advances, you are supporting the Royal Society of Chemistry to help the chemical science community make the world a better place.

With best wishes,

Prof Andrea Pucci  
Associate Editor, RSC Advances

\*\*\*\*\*

REVIEWER REPORT(S):  
Referee: 1

Recommendation: Accept

Comments:  
I agree to accept this manuscript for publication on the RSC.

Additional Questions:  
Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: Yes

Does the data provided fulfil the journal's data requirements?



See Journal specific guidelines: <a href="https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds" target="\_new">https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds</a>: Yes

Is the experimental section sufficiently detailed to allow others to reproduce the work?: Yes

Are the reported claims adequately discussed in the context of the literature?: Yes

Are the number of tables and figures in the manuscript appropriate and clear?: Yes

\*\*\*\*\*

If you need to contact the journal, please use the email address [advances@rsc.org](mailto:advances@rsc.org)

\*\*\*\*\*

#### DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: [www.rsc.org](http://www.rsc.org)

**Decision on submission to RSC Advances - RA-ART-09-2022-005673.R1**

1 message

RSC Advances <onbehalf@manuscriptcentral.com>  
Reply-To: advances@rsc.org  
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Thu, Oct 27, 2022 at 9:17 PM

27-Oct-2022

Dear Mr Fahmi:

Manuscript ID: RA-ART-09-2022-005673.R1

TITLE: Naproxen Release Study upon Carbon dots coated Magnetite Nanohybrid as Versatile Theranostic of HeLa Cancer Cells

Thank you for submitting your revised manuscript to RSC Advances. I am pleased to accept your manuscript for publication in its current form. I have copied any final comments from the reviewer(s) below.

You will shortly receive a separate email from us requesting you to submit a licence to publish for your article, so that we can proceed with the preparation and publication of your manuscript. We will email you information on how to access your RSC Advances article proofs when they are ready.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>.

How can we improve our open access publishing service for you?

Share your OA feedback in a short telephone interview in English or Mandarin to help us improve our open access publishing processes and receive a £25 Amazon voucher (or local equivalent) for your time. Find out more here: <https://www.smartsurvey.co.uk/s/OpenAccess>.

We are offering all corresponding authors who are not already members of the Royal Society of Chemistry one year's Affiliate membership as part of their APC. If you would like to find out more please email [membership@rsc.org](mailto:membership@rsc.org), including the promo code OA100 in your message. Learn all about our member benefits at <https://www.rsc.org/membership-and-community/join/#benefit>.

Promote your research, accelerate its impact – find out more about our article promotion services here: <https://rsc.li/promoteyourresearch>.

If you would like us to promote your article on our Twitter account @RSCAdvances please fill out this form: <https://form.jotform.com/212705294847058>. Alternatively, if you would like your article to be considered for further promotion via our WeChat channels then please do let us know.

By publishing your article in RSC Advances, you are supporting the Royal Society of Chemistry to help the chemical science community make the world a better place.

With best wishes,

Prof Andrea Pucci  
Associate Editor, RSC Advances

\*\*\*\*\*

REVIEWER REPORT(S):  
Referee: 1

Recommendation: Accept

Comments:  
I agree to accept this manuscript for publication on the RSC.

Additional Questions:  
Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: Yes

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: <a href="https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds" target="\_new">https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds</a>: Yes

Is the experimental section sufficiently detailed to allow others to reproduce the work?: Yes

Are the reported claims adequately discussed in the context of the literature?: Yes

Are the number of tables and figures in the manuscript appropriate and clear?: Yes

\*\*\*\*\*

If you need to contact the journal, please use the email address [advances@rsc.org](mailto:advances@rsc.org)

\*\*\*\*\*

#### DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: [www.rsc.org](http://www.rsc.org)